首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Control of glaucoma by reduced dosage guanethidine-adrenaline formulation.
【2h】

Control of glaucoma by reduced dosage guanethidine-adrenaline formulation.

机译:通过减少剂量的胍乙啶-肾上腺素制剂控制青光眼。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effect of formulations of guanethidine and adrenaline of different composition has been tested in rabbits and in patients with glaucoma. The concentrations of guanethidine and adrenaline used for the rabbits were 5.0% and 1.0%; 2.5% and 0.5%; 1.0% and 0.2%; 0.5% and 0.1%. All except the lowest combination were equally effective in the magnitude of the decrease in intraocular pressure brought about and in their duration of activity. Two formulations containing guanethidine and adrenaline at concentrations of 3.0% and 0.5% and 1.0% and 0.2% respectively (formulated as Ganda drops by Smith and Nephew Pharmaceuticals Ltd) were tested in a blind, cross-over, short-term clinical trial on 20 patients. The drops containing the lower concentration of drugs were as effective as those of higher concentration. These results lead us to believe that most patients who respond to this treatment could be put on a reduced dosage regimen, which should result in a decreased incidence and severity of side effects.
机译:已经在兔子和青光眼患者中测试了不同组成的胍乙啶和肾上腺素制剂的效果。用于家兔的胍乙啶和肾上腺素浓度分别为5.0%和1.0%; 2.5%和0.5%; 1.0%和0.2%; 0.5%和0.1%。除了最低限度的组合外,所有组合在降低眼内压的幅度及其活动持续时间内均有效。在20天的盲,交叉,短期临床试验中测试了两种分别含有浓度分别为3.0%和0.5%,1.0%和0.2%的胍乙啶和肾上腺素的制剂(由Smith和Nephew Pharmaceuticals Ltd配制成Ganda滴剂)进行了测试。耐心。包含较低浓度药物的滴剂与较高浓度药物的滴剂一样有效。这些结果使我们相信,对这种治疗有反应的大多数患者可以采取减少剂量的方案,这将导致副作用的发生率和严重性降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号